# EDGAR Filing Document

**Accession Number:** 0001501989
**File Stem:** 0001193125-25-180756
**Filing Date:** 2025-8
**Character Count:** 2297
**Document Hash:** 7bcb86700bf923e0fb9fa2b2543cd951
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-180756.hdr.sgml**: 20250917

**ACCESSION NUMBER**: 0001193125-25-180756

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250814

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CytomX Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001501989
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 273521219
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 151 OYSTER POINT BLVD.
- **STREET 2:** SUITE 400
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650.515.3185

**MAIL ADDRESS:**
- **STREET 1:** 151 OYSTER POINT BLVD.
- **STREET 2:** SUITE 400
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**CytomX Therapeutics, Inc.** 

**151 Oyster Point Blvd., Suite 400** 

**South San Francisco, CA 94080** 

August 14, 2025

**<u>VIA EDGAR</u>**

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attention: Chris Edwards

---

| | |
|:---|:---|
| **Re:** | **CytomX Therapeutics, Inc.**  |

---

**Registration Statement on Form S-3 (File No. 333-289365)** 

To the addressee set forth above:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission of the effective date of the above-referenced Registration Statement on Form S-3 (the "Registration Statement") of CytomX Therapeutics, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on August 18, 2025, or as soon as practicable thereafter.

Thank you for your assistance in this matter.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **CytomX Therapeutics, Inc.** | **CytomX Therapeutics, Inc.** |
| By: | /s/ Christopher W. Ogden |
|  | Christopher W. Ogden |
|  | Chief Financial Officer |

---

CC: Sean A. McCarthy, CytomX Therapeutics, Inc.

Mark V. Roeder, Latham & Watkins LLP

John C. Williams, Latham & Watkins LLP